Issues
Cancer Research
Table of Contents
Advances in Brief
A Mutant Epidermal Growth Factor Receptor Targeted to Lung Epithelium Inhibits Asbestos-induced Proliferation and Proto-Oncogene Expression1
Biochemistry and Biophysics
Experimental Therapeutics
Hepatobiliary Damage and Changes in Hepatic Gene Expression Caused by the Antitumor Drug Ecteinascidin-743 (ET-743) in the Female Rat1
Novel Chondroitin Sulfate-binding Cationic Liposomes Loaded with Cisplatin Efficiently Suppress the Local Growth and Liver Metastasis of Tumor Cells in Vivo1
Sulfonamide Anilides, a Novel Class of Histone Deacetylase Inhibitors, Are Antiproliferative against Human Tumors
Carcinogenesis
Clinical Investigations
Endocrinology
Epidemiology and Prevention
Immunology
Impaired Infiltration of Tumor-specific Cytolytic T Cells in the Absence of Interferon-γ despite Their Normal Maturation in Lymphoid Organs during CD137 Monoclonal Antibody Therapy1
Molecular Biology and Genetics
Gene Expression Profiles with Activation of the Estrogen Receptor α-Selective Estrogen Receptor Modulator Complex in Breast Cancer Cells Expressing Wild-Type Estrogen Receptor1
Lowered Oxygen Tension Induces Expression of the Hypoxia Marker MN/Carbonic Anhydrase IX in the Absence of Hypoxia-inducible Factor 1α Stabilization: A Role for Phosphatidylinositol 3′-Kinase1
Tumor Biology
The N-ras Proto-oncogene Can Suppress the Malignant Phenotype in the Presence or Absence of Its Oncogene1
Virology
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.